| The Efficacy and Safety of Intradermal Acupuncture for Acute Herpes Zoster (NCT05348382) | The Third Affiliated hospital of Zhejiang Chinese Medical University | 2022-07-04 |
| Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage (NCT06334861) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2022-06-23 |
| Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions (NCT05811754) | GlaxoSmithKline | 2022-05-09 |
| Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older (NCT05304351) | Curevo Inc | 2022-02-02 |
| A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India (NCT05219253) | GlaxoSmithKline | 2022-02-02 |
| Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers (NCT05245838) | Dynavax Technologies Corporation | 2022-01-10 |
| A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine (NCT05047770) | GlaxoSmithKline | 2021-10-07 |
| Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) (NCT05082688) | Radboud University Medical Center | 2021-09-20 |
| Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years (NCT04869982) | GlaxoSmithKline | 2021-05-14 |
| Recombinant Zoster Vaccine in Stable SLE Patients (NCT04516408) | RenJi Hospital | 2021-04-20 |
| Prospective Observation of the Fluoroscopy-guided Cervical Epidural Approach Using the Contralateral Oblique View (NCT04774458) | Asan Medical Center | 2021-03-04 |
| The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata (NCT04239521) | Momentum Data | 2020-10-01 |
| Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents (NCT04523246) | University of Oklahoma | 2020-09-01 |
| Persistence of Protection by Shingrix (NCT04169009) | University of Colorado, Denver | 2020-07-28 |
| A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults (NCT05639803) | Shanghai Institute Of Biological Products | 2020-07-07 |
| Study on Efficacy of Attenuated Zoster Vaccine, Live (NCT04334577) | Changchun BCHT Biotechnology Co. | 2020-04-20 |
| Occlusion vs Standard Treatment for the Treatment of Herpes Zoster (NCT04258930) | Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. | 2020-02-26 |
| HIV Indicator Diseases in Hospital and Primary Care (NCT05225493) | Erasmus Medical Center | 2020-01-01 |
| A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response (NCT04176939) | GlaxoSmithKline | 2019-12-09 |
| A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant (NCT04006808) | GlaxoSmithKline | 2019-10-25 |
| Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT (NCT04099706) | Odense University Hospital | 2019-09-19 |
| Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster (NCT04091451) | GlaxoSmithKline | 2019-09-17 |
| Clinical and Economic Impact of Herpes Zoster in Cancer Patients (NCT06207487) | AC Camargo Cancer Center | 2019-09-01 |
| Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab (NCT03798691) | University of Wisconsin, Madison | 2019-05-28 |
| The Superiority of Contralateral Oblique View for Mid-thoracic Epidural Assess (NCT03789955) | Asan Medical Center | 2019-02-22 |
| Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects (NCT03820414) | Curevo Inc | 2019-01-03 |
| A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years (NCT04072497) | Shanghai Institute Of Biological Products | 2018-11-20 |
| Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia (NCT03809702) | B.P. Koirala Institute of Health Sciences | 2018-07-15 |
| A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 (NCT03563183) | GlaxoSmithKline | 2018-06-05 |
| Treatment of Chronic Postherpetic Pain With Fat Grafting (NCT03584061) | Odense University Hospital | 2018-05-01 |
| Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older (NCT03439657) | GlaxoSmithKline | 2018-04-12 |
| Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster (NCT03553472) | University of Wisconsin, Madison | 2018-01-01 |
| Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age (NCT03314103) | Jiangsu Province Centers for Disease Control and Prevention | 2017-10-06 |
| Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation (NCT03192319) | Seoul National University Hospital | 2017-07-01 |
| Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia (NCT03120962) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2017-05-01 |
| Tzanck Smear With Methylene Blue Stain for Herpes (NCT03178747) | Chulalongkorn University | 2017-03-07 |
| Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age (NCT02979639) | GlaxoSmithKline | 2017-01-16 |
| Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients (NCT03016884) | HaEmek Medical Center, Israel | 2017-01-01 |
| Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo (NCT02902822) | Centro Studi Gised | 2016-10-01 |
| A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults (NCT02723773) | GlaxoSmithKline | 2016-04-16 |
| Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older (NCT02735915) | GlaxoSmithKline | 2016-04-11 |
| Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies. (NCT02690207) | GlaxoSmithKline | 2016-03-16 |
| Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France (NCT02487472) | GlaxoSmithKline | 2016-01-19 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier (NCT02581410) | GlaxoSmithKline | 2015-12-15 |
| Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older (NCT02526745) | Beijing Chaoyang District Centre for Disease Control and Prevention | 2015-12-01 |
| Enhancing a Sustainable Pharmacy-based Immunization Program in Two States (NCT02615470) | Auburn University | 2015-11-01 |
| Postherpetic Neuralgia After Herpes Zoster and Incident Dementia Risk (NCT07399288) | China Medical University Hospital | 2015-10-01 |
| Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062) (NCT02519855) | Merck Sharp & Dohme LLC | 2015-09-11 |
| A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia (NCT02412917) | ContraVir Pharmaceuticals, Inc. | 2015-06-01 |
| Herpes Zoster Prevalence in Frailty Consultations (NCT02832986) | University Hospital, Toulouse | 2015-01-01 |
| Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age (NCT02075515) | GlaxoSmithKline | 2014-08-13 |
| A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014) (NCT02180295) | Merck Sharp & Dohme LLC | 2014-07-01 |
| The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept (NCT03604406) | Kevin Winthrop | 2014-05-08 |
| Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds (NCT02114333) | University of Colorado, Denver | 2014-05-01 |
| Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster (NCT02151240) | Cttq | 2014-05-01 |
| Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant (NCT02058589) | GlaxoSmithKline | 2014-03-20 |
| Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older (NCT02045836) | GlaxoSmithKline | 2014-03-05 |
| Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older (NCT02052596) | GlaxoSmithKline | 2014-02-07 |
| Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over (NCT03116594) | SK Chemicals Co., Ltd. | 2014-01-03 |
| Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older (NCT01954251) | GlaxoSmithKline | 2013-10-03 |
| Phase III Study of ASP2151 in Herpes Zoster Patients (NCT01959841) | Maruho Co., Ltd. | 2013-08-01 |
| A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above (NCT01873365) | GlaxoSmithKline | 2013-06-29 |
| Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years (NCT01777321) | GlaxoSmithKline | 2013-06-17 |
| Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster (NCT01827839) | GlaxoSmithKline | 2013-06-10 |
| Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ (NCT02958345) | Tulane University | 2013-06-01 |
| Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older (NCT01751165) | GlaxoSmithKline | 2013-03-12 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy (NCT01798056) | GlaxoSmithKline | 2013-03-06 |
| Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers (NCT01767467) | GlaxoSmithKline | 2013-03-01 |
| Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy (NCT01772160) | GlaxoSmithKline | 2013-02-26 |
| Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) (NCT01527370) | Merck Sharp & Dohme LLC | 2012-10-31 |
| Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A (NCT01610414) | GlaxoSmithKline | 2012-07-13 |
| Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster (NCT01327144) | EMS | 2012-06-01 |
| ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024) (NCT01600079) | Merck Sharp & Dohme LLC | 2012-05-15 |
| ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) (NCT01556451) | Merck Sharp & Dohme LLC | 2012-04-01 |
| Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1) (NCT01505647) | Merck Sharp & Dohme LLC | 2012-04-01 |
| Herpes Zoster Vaccine for Bone Marrow Transplant Donors (NCT01573182) | University of Sydney | 2012-04-01 |
| A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009) (NCT01527383) | Merck Sharp & Dohme LLC | 2012-02-21 |
| A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013) (NCT01460719) | Merck Sharp & Dohme LLC | 2012-01-24 |
| Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital (NCT01483378) | NYU Langone Health | 2012-01-01 |
| Distances From Cricoid Cartilage to the Targets of Stellate Ganglion Block (NCT01601925) | Yonsei University | 2012-01-01 |
| A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2) (NCT01385566) | Merck Sharp & Dohme LLC | 2011-09-01 |
| Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045) (NCT01391546) | Merck Sharp & Dohme LLC | 2011-06-20 |
| Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029) (NCT01245751) | Merck Sharp & Dohme LLC | 2011-04-01 |
| Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects (NCT01295320) | GlaxoSmithKline | 2011-02-28 |
| Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study (NCT01213810) | University of Zurich | 2010-12-01 |
| A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001) (NCT01229267) | Merck Sharp & Dohme LLC | 2010-11-30 |
| Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects (NCT01165203) | GlaxoSmithKline | 2010-09-30 |
| T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 (NCT01911065) | Stanford University | 2010-09-01 |
| ZOSTAVAX® in Renal Transplant Patients (NCT01137669) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-09-01 |
| Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older (NCT01165177) | GlaxoSmithKline | 2010-08-02 |
| Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older (NCT01165229) | GlaxoSmithKline | 2010-08-02 |
| Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia (NCT01166295) | Analgesic Solutions | 2010-07-01 |
| Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults (NCT01086449) | GlaxoSmithKline | 2010-03-04 |
| Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A (NCT00920218) | GlaxoSmithKline | 2009-07-14 |
| A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster (NCT00900783) | Bristol-Myers Squibb | 2009-05-01 |
| Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy (NCT00851786) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-04-29 |
| Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles (NCT00921934) | Pascoe Pharmazeutische Praeparate GmbH | 2009-04-01 |
| A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003) (NCT00886613) | Merck Sharp & Dohme LLC | 2009-03-01 |
| Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years (NCT00802464) | GlaxoSmithKline | 2009-01-12 |
| A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED) (NCT00696709) | Merck Sharp & Dohme LLC | 2008-12-12 |